Widely-used hormone drug associated with increased risk of benign brain tumor at high doses
High doses of a widely-used drug used in the hormonal treatment of conditions such as excessive hair growth, early puberty, prostate cancer, are linked to an increased risk of meningioma—the most common type of benign brain tumor, finds a University of Bristol-led study of over 8-million patients. The study is published in Scientific Reports.